Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Positive 61.3%

Neg 0% Neu 0% Pos 61.3%

Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.